Through the 90-day period concluding February 19, 2026, Recursion Pharmaceuticals's top three insider stakeholders include Other Ventures Iv, L.P. Lux (30.31Mn shares), TenPercentOwner Investment Co Pjsc Mubadala (12.99Mn shares), Director Blake Borgeson (6.43Mn shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Ventures Iv, L.P. Lux | 30,308,614 | 09 Dec, 2021 | |
| Investment Co Pjsc Mubadala | 12,985,927 | 03 Mar, 2023 | |
| Blake Borgeson | 6,429,863 | 06 Feb, 2026 | |
| Zachary Bogue | 3,736,341 | 06 Jul, 2023 | |
| Collective Iv, L.P. Data | 3,726,963 | 22 Apr, 2021 | |
| Najat Khan | Ceo And President | 2,304,663 | 10 Feb, 2026 |
| Dean Y Li | 1,661,909 | 06 Jan, 2026 | |
| Michael Secora | Chief Financial Officer | 1,487,694 | 19 Nov, 2024 |
| Ben R Taylor | Chief Financial Officer | 1,220,683 | 10 Feb, 2026 |
| David Hallett | Chief Scientific Officer | 1,109,059 | 10 Feb, 2026 |
| Christopher Gibson | 933,821 | 06 Feb, 2026 | |
| Tina Marriott | President And Coo | 506,852 | 19 Nov, 2024 |
| David J Mauro | Chief Medical Officer | 225,429 | 19 Nov, 2024 |
| Zavain Dar | 142,329 | 06 Jan, 2026 | |
| Shafique Virani | Chief Business Officer | 136,748 | 18 Jan, 2024 |
| Franziska Michor | 127,053 | 23 Jun, 2025 | |
| Ramona Doyle | Chief Medical Officer | 121,110 | 16 May, 2022 |
| Robert Hershberg | 73,732 | 23 Jun, 2025 | |
| Terry-Ann Burrell | 71,254 | 03 Jul, 2024 | |
| R. Martin Chavez | 60,078 | 03 Apr, 2024 | |
| Elaine D Sun | 47,557 | 23 Jun, 2025 | |
| Namandje Bumpus | 47,557 | 23 Jun, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 06 Feb, 2026 | Ben R Taylor | Class A Common Stock | A | 446,279 | $0.00 | 1,207,829 | D | A |
| 06 Feb, 2026 | Ben R Taylor | Class A Common Stock | A | 24,254 | $0.00 | 1,232,083 | D | A |
| 06 Feb, 2026 | Ben R Taylor | Class A Common Stock | D | 11,400 | $3.98 | 1,220,683 | D | F |
| 06 Feb, 2026 | Christopher Gibson | Class A Common Stock | D | 10,364 | $3.56 | 933,821 | D | F |
| 06 Feb, 2026 | Christopher Gibson | Class A Common Stock | A | 30,346 | $0.00 | 944,185 | D | A |
| 06 Feb, 2026 | David Hallett | Class A Common Stock | D | 11,400 | $3.98 | 1,109,059 | D | F |
| 06 Feb, 2026 | David Hallett | Class A Common Stock | A | 502,064 | $0.00 | 1,096,205 | D | A |
| 06 Feb, 2026 | David Hallett | Class A Common Stock | A | 24,254 | $0.00 | 1,120,459 | D | A |
| 06 Feb, 2026 | Najat Khan | Class A Common Stock | D | 10,364 | $3.98 | 2,304,663 | D | F |
| 06 Feb, 2026 | Najat Khan | Class A Common Stock | A | 30,346 | $0.00 | 2,315,027 | D | A |
| 06 Feb, 2026 | Najat Khan | Class A Common Stock | A | 1,673,546 | $0.00 | 2,284,681 | D | A |
| 04 Feb, 2026 | Christopher Gibson | Class A Common Stock | D | 40,000 | $4.12 | 913,839 | D | S |
| 04 Feb, 2026 | Christopher Gibson | Class A Common Stock | A | 40,000 | $0.00 | 953,839 | D | C |
| 03 Feb, 2026 | Blake Borgeson | Class A Common Stock | D | 220,000 | $4.20 | 6,429,863 | D | S |
| 20 Jan, 2026 | Christopher Gibson | Class A Common Stock | A | 40,000 | $0.00 | 953,839 | D | C |
| 20 Jan, 2026 | Christopher Gibson | Class A Common Stock | D | 40,000 | $4.47 | 913,839 | D | S |
| 06 Jan, 2026 | Blake Borgeson | Class A Common Stock | D | 220,000 | $4.36 | 6,649,863 | D | S |
| 05 Jan, 2026 | Christopher Gibson | Class A Common Stock | D | 40,000 | $4.25 | 933,839 | D | S |
| 05 Jan, 2026 | Christopher Gibson | Class A Common Stock | A | 60,000 | $0.00 | 973,839 | D | C |
| 05 Jan, 2026 | Christopher Gibson | Class A Common Stock | D | 20,000 | $0.00 | 913,839 | D | G |